Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Cedar Grove Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD+12.8%
YTD-13.2%
Positioning StanceNEUTRAL
Market CapSMID Cap
GeographyUS
Digest Analysis
Quick Take
"Rebounding from Q1 losses by diversifying into 16 positions across healthcare, biotech, and consumer sectors while aggressively shorting overvalued names."
Executive Summary
Cedar Grove Capital Management returned 12.8% net in Q2 2026, rebounding from a difficult Q1 marked by the SaaS downturn and US-Iran conflict. The fund now holds 16 positions across healthcare, biotechnology, consumer discretionary, and technology, with a long/short strategy that delivered alpha through aggressive short positions in overvalued names. The manager explicitly avoids the AI momentum trade, viewing hyperscaler spending on infrastructure as unsustainable and reminiscent of past parabolic sector moves. Instead, the portfolio focuses on unloved small-cap companies with strong fundamentals, including telehealth plays like HIMS (second largest holding) and Hydreight Technologies, biotechnology positions in QURE, NKTR, and ABVX with positive clinical data, and grid modernization exposure through Tantalus Systems. Key detractors included KITS Eyewear (due to unwanted bitcoin exposure) and Sanuwave Health (Medicare reimbursement headwinds). The manager emphasizes patience and diversification, positioning for eventual capital rotation away from AI into fundamentally improving small caps. Despite near-term volatility, the long-term thesis remains intact with a marathon mindset.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
62%
CautiousHigh
Moderate (62%)
The manager runs a 16-position portfolio with named holdings and specific position sizing commentary (HIMS as second largest holding, KITS was top holding before reduction). Multiple positions are discussed with clear theses: HIMS for telehealth, QURE/CLPT for FDA regulatory changes, ABVX for ulcerative colitis drug data, EVLV for weapons detection growth. The manager explicitly states willingness to size up positions during drawdowns (ABVX) and discusses holding through volatility. However, the portfolio is moderately diversified (16 positions vs concentrated 5-10), and some hedging language exists around timing and market uncertainty. The manager also trimmed several positions (REAL, MTY.TO, KITS) for risk management. This places conviction in the moderate range, above 0.55 due to named positions and sizing commentary, but below 0.75 due to diversification and tactical trimming.
Growth Outlook
38%
BearishBullish
Neutral (38%)
The manager acknowledges Q2 was much better for markets following the Middle East ceasefire and falling oil prices/interest rates, but expresses significant concern about the AI trade dominating flows and leaving smaller companies undervalued. The manager explicitly states that sectors going parabolic eventually face reality, though timing is uncertain. The outlook is cautious with selective optimism for eventual capital rotation, but the dominant tone is one of wariness about current market dynamics favoring momentum over fundamentals.
Risk Appetite
35%
DefensiveAggressive
Defensive (35%)
The manager increased portfolio positions from concentrated to 16 names, diversified across sectors and strategies including event-driven, and aggressively added short positions targeting overvalued names. This represents a moderately risk-on posture with tactical hedging. The manager is deploying capital selectively (HIMS as second largest holding, new positions in QURE, CLPT, LNSR, NURS.V, GRID.TO) while maintaining defensive shorts. The positioning is tilted toward risk but with meaningful hedges and diversification to reduce volatility, placing it in the mildly positive range.
Capital Deployment
25%
De-riskingDeploying
De-risking (25%)
The manager added multiple new positions during Q2 (LNSR, QURE, CLPT, HIMS, NURS.V, GRID.TO) and increased positions in NKTR, ABVX, TOI, and EVLV. However, the manager also trimmed or exited positions in KITS, SNWV, REAL, and MTY.TO, and realized multiple short positions. The net activity represents capital rotation and reallocation rather than aggressive deployment of new cash. The manager diversified from a concentrated portfolio to 16 positions, suggesting redeployment of existing capital across more names rather than putting significant new cash to work. No cash level changes are disclosed. This represents modest net deployment activity, scoring in the low positive range.
Forward Guidance
20%
CautiousExpansionary
Cautious (20%)
The manager states they are not waiting around for doomsday and have diversified into more companies and sectors, indicating selective deployment. However, the dominant message is patience and waiting for capital rotation away from AI. The manager explicitly says they will continue to exert patience as the volatile year continues, emphasizing a marathon mindset. There is some deployment activity (new positions added) but the overall bias is toward monitoring and patience rather than aggressive capital deployment, placing this in the mildly positive range.
Language Signal
15%
BearishBullish
Bearish (15%)
The letter contains balanced directional language. Bullish terms include: fundamentally improving, strong tailwinds, attractive, viable options, outstanding earnings, positive clinical data, long-term winner, intrinsic values. Bearish terms include: difficult investing environment, unsustainable levels, parabolic, collateral damage, punishing, volatile, tumultuous, hiccups, detractors. The manager also uses cautious framing around AI risks and market dynamics. The net balance leans slightly positive given the emphasis on long-term opportunities and fundamentally sound positions, but the significant risk discussion and market concerns keep this in the mildly positive range.
Perceived Risk
55%
Low RiskElevated
Moderate Risk (55%)
The manager identifies specific, named risks with meaningful discussion: the AI trade sucking oxygen out of the market, unsustainable hyperscaler spending with unknown end state, parabolic sectors eventually facing reality, and market punishment of consumer discretionary stocks. The manager also discusses specific position risks like Medicare reimbursement changes affecting SNWV and bitcoin exposure in KITS. However, the risk discussion is balanced with opportunity framing, and the manager is actively positioning for eventual capital rotation rather than expressing alarm. The risks are acknowledged as real but manageable through diversification and patience. This places perceived risk in the moderate range, above 0.35 due to specific risk identification, but below 0.60 as risks are not framed as systemic or existential.
Opportunity Density
65%
ScarceAbundant
Abundant (65%)
The manager added six new positions in Q2 (LNSR, QURE, CLPT, HIMS, NURS.V, GRID.TO) and increased four existing positions, indicating a relatively rich opportunity set in specific areas. The manager describes exploiting mispricings opened by traders (QURE, CLPT), finding opportunities in unloved but fundamentally improving positions, and seeing multiple sectors with strong tailwinds (telehealth, gene therapy, grid modernization). However, the manager also notes that smaller companies are still clawing back to intrinsic values and trimmed some positions due to market conditions. The opportunity set is characterized as selective rather than broad, with good ideas in defined areas but requiring patience. This places opportunity density in the moderate-to-good range.
Time Horizon
70%
Short-TermLong-Term
Decade+ (70%)
The manager explicitly emphasizes a long-term mindset throughout the letter, stating they are running a marathon not a sprint, and labeling the quarterly update with patience is a virtue. The manager references a long history with HIMS going back to 2021, discusses holding positions through volatility (ABVX, NKTR need more time), and frames the investment approach around long-term tailwinds in telehealth and other sectors. However, the manager also engages in tactical trading (quick trade in CMG, realized multiple shorts in Q2) and discusses near-term catalysts like FDA filings in late Q3 for QURE. The dominant message is multi-year patience with some tactical activity, placing the time horizon in the 2-5 year range typical of public equities funds with a value orientation.